Ar­row­head touts hep B da­ta, shares rock­et up; Eli Lil­ly's an­i­mal health unit files big IPO

→ Ar­row­head Phar­ma­ceu­ti­cals saw its share price $AR­WR rock­et up 43% on Thurs­day morn­ing af­ter the com­pa­ny un­veiled new da­ta that it says sup­port the work they’re do­ing on an RNAi ther­a­py for he­pati­tis B. They call the ther­a­py “po­ten­tial­ly cu­ra­tive” in their re­lease. Their state­ment: “The da­ta demon­strate that three month­ly dos­es of ARO-HBV led to a max­i­mum re­duc­tion in cir­cu­lat­ing HBV sur­face anti­gen (HB­sAg) of 4.0 log10, with mean re­duc­tions of ap­prox­i­mate­ly 2.0 log10 on day 85 in the 100 mg co­hort and 1.4 log10 on day 71 in the 200mg co­hort (cur­rent­ly the last com­plete da­ta point avail­able). All eight pa­tients achieved greater than 1.0 log10 re­duc­tions in cir­cu­lat­ing HB­sAg.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER